Physician profile
Donna Klitzman
NPI 1295824563
$5,453.85
in general payments reported to CMS, 2019-2025
39 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $172 · 2021: $295 · 2022: $867 · 2023: $1,129 · 2024: $875 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,986.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,253.40 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,233.72 | 2019-2025 | Nucala, Trelegy Ellipta |
| Mylan Specialty L.P. | $389.28 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.46 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva |
| Genzyme Corporation | $249.36 | 2019-2025 | |
| Insmed, INC. | $239.75 | 2022-2025 | Arikayce |
| Novartis Pharmaceuticals Corporation | $217.45 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $186.07 | 2019-2025 | Dupixent |
| Inari Medical, INC. | $143.59 | 2022 | |
| Amgen INC. | $133.03 | 2022-2025 | Tezspire, Tavneos |
| Csl Behring | $89.87 | 2020-2023 | Hizentra |
| Verona Pharma, INC. | $89.80 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $83.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $64.48 | 2021-2024 | Zerbaxa, Dificid, Recarbrio |
| Philips North America LLC | $61.27 | 2019-2024 | (Ak6) Vest Therapy |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $56.59 | 2021-2024 | Aralast |
| Harmony Biosciences LLC | $53.49 | 2023-2024 | Wakix |
| Axsome Therapeutics, INC. | $50.05 | 2023 | Sunosi |
| Viatris Specialty LLC | $48.65 | 2025 | Yupelri |
| United Therapeutics Corporation | $46.96 | 2019-2025 | Tyvaso |
| Grifols USA, LLC | $39.77 | 2023-2024 | Xembify |
| Ani Pharmaceuticals, INC. | $38.37 | 2025 | Purified Cortrophin Gel |
| Inspire Medical Systems, INC. | $32.11 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $29.05 | 2019 | |
| Pfizer INC. | $28.51 | 2019 | |
| Mallinckrodt Enterprises LLC | $28.37 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.00 | 2022-2024 | |
| Shire North American Group INC | $26.99 | 2019 | |
| Genentech USA, INC. | $26.04 | 2019-2024 | Xolair |
| Sunovion Pharmaceuticals INC. | $24.02 | 2019 | |
| Lilly USA, LLC | $19.76 | 2025 | Zepbound |
| Inogen, INC. | $18.28 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Advanced Respiratory, INC | $15.45 | 2019 | |
| Astellas Pharma US INC | $14.91 | 2020 | |
| Pulmonx Corporation | $14.26 | 2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Mallinckrodt Hospital Products INC. | $14.09 | 2020 | |
| Electromed, INC. | $13.26 | 2019 | |
| Optinose US, INC. | $13.20 | 2024 | |
| Sanofi Pasteur INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Klitzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.